Latest

Nektar reports Q2 2026 results, details Phase 3 rezpegaldesleukin timeline

Nektar says its first Phase 3 atopic dermatitis trials began in July, with a BLA path targeted for 2029 and cash into the third quarter of 2028.

SEC filing